about
Group B Streptococcus vaccine: state of the artA maternal vaccine against group B Streptococcus: past, present, and futureGroup B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countriesStimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal diseaseAlpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein.Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B Streptococci from lungs of infected mice.Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B StreptococcusNeonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis.Group B streptococcal conjugate vaccines.Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.A Safe and Stable Neonatal Vaccine Targeting GAPDH Confers Protection against Group B Streptococcus Infections in Adult Susceptible Mice.Polyacrylamide gel electrophoresis of the capsular polysaccharides of Escherichia coli K1 and other bacteria.Sialic acid content and surface hydrophobicity of group B streptococciRecombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier proteinStreptococcal diseases worldwide: present status and prospects.O-Acetylation of sialic acid on Group B Streptococcus inhibits neutrophil suppression and virulence.Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.Opsonization of Streptococcus agalactiae of bovine origin by complement and antibodies against group B polysaccharideAdherence of group B streptococci to adult and neonatal epithelial cells mediated by lipoteichoic acidImmune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.Genetic and biochemical modulation of sialic acid O-acetylation on group B Streptococcus: phenotypic and functional impact.Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein.Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization.Les maladies à streptocoques dans le monde: situation actuelle et perspectives.Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models.Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches.
P2860
Q26796438-DB5B13BC-F8ED-4F46-84CD-5D3E85F7F8CDQ26822039-8B25897A-C99C-4D24-B261-C3544D99EE8FQ28075884-4E1821D3-FE90-4EC2-BA21-787D578344EAQ33614322-93A38128-F121-4B02-90EA-DBE0F0C665BAQ33864281-5723BA8B-DFA6-4F5E-8D39-2F3C8C97729BQ33867469-AF1A3B26-2934-4B7F-B696-DB1E915F0EADQ34130285-C3FCED5D-AB5D-48A1-A93F-ADF21B5BE9ACQ34184513-7AFC6A77-4D17-46B8-BB92-0E89758A6032Q34262847-DA8B55D3-6204-4101-B9DD-93015D2C75DEQ34532914-F3387F48-AD0A-461B-8D07-ABF2BE463365Q34975076-F9AB386E-082D-4551-A8D3-62603350A943Q34985330-B4355AA2-70D2-408A-A7A0-87ECC5D8519FQ35115488-AE3C4E70-14C9-4D89-8163-85C6F081527CQ35470773-DDFE3E97-CC71-486A-93E7-629981AC854EQ35870249-9892C16E-32D0-4FFA-A98D-4CEA27C123A8Q36204985-2F440534-B738-4A07-A9C8-672C44A2BBC8Q36505510-0C9FCBD7-4B3B-4C29-B6EC-88A7B4883E18Q36746962-F91143BB-1CEB-47CC-8742-655C5E3BD148Q36799487-8B008F27-31A0-45CB-8447-04B99DB0A4C5Q36806314-C9B0CBE5-6634-43EF-B905-45635AC67D8FQ36951421-AC4C885E-9BE7-4326-AE91-7A8BDFC00E53Q36971152-1626EB4B-CFB5-4977-BDC9-11EE66E425C9Q37009248-A06E244B-CC6A-42D3-BD1A-CD375F96E145Q37361495-C0F3C433-97E9-45BD-86F2-A2970F0E6878Q37376671-B82A38C0-AC97-4219-92BD-5BF37948ACDFQ37630658-8538F095-C36D-43FA-AFF6-56FB367E4490Q40344808-868D5318-A69D-4FB0-B949-332C4284DC28Q45743550-C4FB23A6-84E1-424F-97B6-3566544AA52BQ50129993-3148A18C-4671-42C8-85BA-F435226AFFEFQ52665560-FF28E92F-EF3B-4CA2-9EAF-F164961A5D39
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Group B streptococcal vaccines.
@en
Group B streptococcal vaccines.
@nl
type
label
Group B streptococcal vaccines.
@en
Group B streptococcal vaccines.
@nl
prefLabel
Group B streptococcal vaccines.
@en
Group B streptococcal vaccines.
@nl
P1476
Group B streptococcal vaccines.
@en
P2093
P304
P577
1985-07-01T00:00:00Z